CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.05) by 1320 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $3.41 million which missed the analyst consensus estimate of $12.00 million by 71.59 percent. This is a 59.16 percent decrease over sales of $8.35 million the same period last year.
CASI Pharmaceuticals Q1 EPS $(0.71) Misses $(0.05) Estimate, Sales $3.41M Miss $12.00M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.